BACKGROUND: During the era of highly active antiretroviral therapy (HAART), the prevalence of HIV-associated central nervous system (CNS) disease has increased despite suppression of plasma viremia. METHODS: In a simian immunodeficiency virus (SIV) model system in which all animals develop AIDS and 90% develop CNS disease by 3 months after inoculation, pigtailed macaques were treated with a regimen of tenofovir disoproxil fumarate, saquinavir, atazanavir, and an integrase inhibitor starting at 12 days after inoculation and were euthanized at approximately 175 days after inoculation. RESULTS: Plasma and cerebrospinal fluid (CSF) viral loads declined rapidly after the initiation of HAART. Brain viral RNA was undetectable at necropsy, but viral DNA levels were not different from those in untreated SIV-infected macaques. CNS inflammation was significantly reduced, with decreased brain expression of major histocompatibility complex class II and glial fibrillary acidic protein and reduced levels of CSF CCL2 and interleukin 6. Brain from treated macaques had significantly lower levels of interferon beta, type 1 interferon-inducible gene myxovirus (influenza) resistance A, and indolamine 2,3-dioxygenase messenger RNA, suggesting that immune hyperactivation was suppressed, and fewer CD4(+) and CD8(+) T cells, suggesting that trafficking of T cells from peripheral blood was reduced. Brain levels of CD68 protein and tumor necrosis factor alpha and interferon gamma RNA were reduced but were not significantly lower, indicating continued CNS inflammation. CONCLUSIONS: These data, generated in a rigorous, high-viral-load SIV-infected macaque model, showed that HAART provided benefits with respect to CNS viral replication and inflammation but that no change in the level of viral DNA and continued CNS inflammation occurred in some macaques.
BACKGROUND: During the era of highly active antiretroviral therapy (HAART), the prevalence of HIV-associated central nervous system (CNS) disease has increased despite suppression of plasma viremia. METHODS: In a simian immunodeficiency virus (SIV) model system in which all animals develop AIDS and 90% develop CNS disease by 3 months after inoculation, pigtailed macaques were treated with a regimen of tenofovir disoproxil fumarate, saquinavir, atazanavir, and an integrase inhibitor starting at 12 days after inoculation and were euthanized at approximately 175 days after inoculation. RESULTS: Plasma and cerebrospinal fluid (CSF) viral loads declined rapidly after the initiation of HAART. Brain viral RNA was undetectable at necropsy, but viral DNA levels were not different from those in untreated SIV-infected macaques. CNS inflammation was significantly reduced, with decreased brain expression of major histocompatibility complex class II and glial fibrillary acidic protein and reduced levels of CSF CCL2 and interleukin 6. Brain from treated macaques had significantly lower levels of interferon beta, type 1 interferon-inducible gene myxovirus (influenza) resistance A, and indolamine 2,3-dioxygenase messenger RNA, suggesting that immune hyperactivation was suppressed, and fewer CD4(+) and CD8(+) T cells, suggesting that trafficking of T cells from peripheral blood was reduced. Brain levels of CD68 protein and tumor necrosis factor alpha and interferon gamma RNA were reduced but were not significantly lower, indicating continued CNS inflammation. CONCLUSIONS: These data, generated in a rigorous, high-viral-load SIV-infected macaque model, showed that HAART provided benefits with respect to CNS viral replication and inflammation but that no change in the level of viral DNA and continued CNS inflammation occurred in some macaques.
Authors: Richard W Price; Robin Parham; Jing Lu Kroll; Stephen A Wring; Brian Baker; Jeff Sailstad; Rebecca Hoh; Teri Liegler; Serena Spudich; Daniel R Kuritzkes; Steven G Deeks Journal: Antivir Ther Date: 2008
Authors: M C Zink; G D Coleman; J L Mankowski; R J Adams; P M Tarwater; K Fox; J E Clements Journal: J Infect Dis Date: 2001-09-10 Impact factor: 5.226
Authors: Daria J Hazuda; Steven D Young; James P Guare; Neville J Anthony; Robert P Gomez; John S Wai; Joseph P Vacca; Larry Handt; Sherri L Motzel; Hilton J Klein; Geethanjali Dornadula; Robert M Danovich; Marc V Witmer; Keith A A Wilson; Lynda Tussey; William A Schleif; Lori S Gabryelski; Lixia Jin; Michael D Miller; Danilo R Casimiro; Emilio A Emini; John W Shiver Journal: Science Date: 2004-07-08 Impact factor: 47.728
Authors: Michael R Weed; Lisa H Gold; Ilham Polis; George F Koob; Howard S Fox; Michael A Taffe Journal: AIDS Res Hum Retroviruses Date: 2004-01 Impact factor: 2.205
Authors: Sheila A Barber; Lucio Gama; Justyna M Dudaronek; Tauni Voelker; Patrick M Tarwater; Janice E Clements Journal: J Infect Dis Date: 2006-02-21 Impact factor: 5.226
Authors: Elizabeth M King; Manminder Kaur; Wei Gong; Christopher F Rider; Neil S Holden; Robert Newton Journal: J Pharmacol Exp Ther Date: 2009-05-12 Impact factor: 4.030
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Payam Tabarsi; Ali S Saber-Tehrani; Parvaneh Baghaei; Mojgan Padyab; Davood Mansouri; Majid Amiri; Mohammad Reza Masjedi; Frederick L Altice Journal: J Int AIDS Soc Date: 2009-07-16 Impact factor: 5.396
Authors: Jamie L Dorsey; Lisa M Mangus; Peter Hauer; Gigi J Ebenezer; Suzanne E Queen; Victoria A Laast; Robert J Adams; Joseph L Mankowski Journal: J Neuropathol Exp Neurol Date: 2015-11 Impact factor: 3.685
Authors: G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford Journal: J Virol Date: 2015-04-01 Impact factor: 5.103
Authors: Heather Carryl; Melanie Swang; Jerome Lawrence; Kimberly Curtis; Herman Kamboj; Koen K A Van Rompay; Kristina De Paris; Mark W Burke Journal: ACS Chem Neurosci Date: 2015-06-19 Impact factor: 4.418
Authors: Weston C Roda; Michael Y Li; Michael S Akinwumi; Eugene L Asahchop; Benjamin B Gelman; Kenneth W Witwer; Christopher Power Journal: J Neurovirol Date: 2017-05-16 Impact factor: 2.643
Authors: Matthew W Breed; Andrea P O Jordan; Pyone P Aye; Cornelis F Lichtveld; Cecily C Midkiff; Faith R Schiro; Beth S Haggarty; Chie Sugimoto; Xavier Alvarez; Netanya G Sandler; Daniel C Douek; Marcelo J Kuroda; Bapi Pahar; Michael Piatak; Jeffrey D Lifson; Brandon F Keele; James A Hoxie; Andrew A Lackner Journal: J Virol Date: 2012-11-14 Impact factor: 5.103